Neuland Laboratories Ltd

NSE
NEULANDLAB •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Neuland Laboratories Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W High in past week
35.3
TTM PE Ratio
Below industry Median
28.3
Price to Book Ratio
High in industry
9.1
Dividend yield 1yr %
Low in industry
0.1
TTM PEG Ratio
PEG TTM is less than 1
0.1
RSI
RSI is mid-range
62.1
MFI
MFI Overbought
73.3

Neuland Laboratories Ltd Key Financials

*All values are in ₹ Cr.

Neuland Laboratories Ltd shareholding Pattern

Promoter
32.8%
Foreign Institutions
22.7%
Mutual Funds
1.8%
Domestic Institutions
6.4%
Public
38.1%

Neuland Laboratories Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
14
Bearish Moving Averages
2
5Day EMA
7,076.60
10Day EMA
6,944.90
12Day EMA
6,887.00
20Day EMA
6,670.80
26Day EMA
6,529.70
50Day EMA
6,084.00
100Day EMA
5,415.00
200Day EMA
4,497.90
Delivery & Volume
Resistance & Support
7,036.13
Pivot
Resistance
First Resistance
7,200.67
Second Resistance
7,399.53
Third Resistance
7,564.07
Support
First Support
6,837.27
Second support
6,672.73
Third Support
6,473.87
Relative Strength Index
62.11
Money Flow Index
73.32
MACD
357.31
MACD Signal
334.74
Average True Range
305.24
Average Directional Index
41.64
Rate of Change (21)
24.91
Rate of Change (125)
73.26

Neuland Laboratories Ltd Company background

Founded in: 1984
Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by Davuluri Sucheth Rao. Neuland Drugs Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. The Company came out with its initial public offering in Apr.94 at a premium of Rs 35 aggregating Rs 5.69 cr, to partfinance the capacity expansion to manufacture bulk drugs and to diversify its productmix. The cost of the project as estimated by ICICI was Rs 15.7 cr.NLLs products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate.During the year 19992000, the company introduced Itraconazole, an antifungal drug and Ipratropium Bromide, an antiasthmatic drug and the R D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form.Mirtrazapine, an antidepressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI.The Company commenced commercial production of Ramipril, a cardiovascular drug for export to certain markets in 2002.The Company commenced commercial production of Citalopram Hydrobromide, an anti depressant, Pirbuterol Acetate, a bronchodilator, Levofloxacin, an anti bacterial, Levetiracetam, an anti convulsant in 2003.A subsidiary company of Neuland Laboratories Ltd was incorporated on January 4, 2007 in the State of Delaware, USA with its principal office in Orange County, California. During the year 20082009, Neuland Laboratories K.K., Japan was incorporated as a subsidiary of Company.During 201213, Company undertook a major reorganisation of businesses aimed at deleveraging on one hand and on other hand narrowing the focus on core activities: APIs, Intermediates and Contract Manufacturing. Consequently, the Company divested its RD activities by selling its Land and Building and some identified intellectual properties to Neuland Pharma Research Private Limited and its Peptides Research activities along with identified intellectual properties to Neuland Health Sciences Private Limited. It entered into a Joint Business Arrangement with API Corporation, Japan, a part of Mitsubishi Chemical, for manufacturing and sale of APIs and Intermediates.During 201314, the Company enhanced its product bouquet by launching 5 more products. It also enhanced its development portfolio to 22 molecules/ APIs created for launch between 2013 and 2016. It opened new office in New Jersey, provide them with quick support and coordinate in various business activities.In November 2016, the Board of Directors of the Company approved the Scheme of Amalgamation of Neuland Health Sciences Private Limited (Holding/ Parent Company) and Neuland Pharma Research Private Limited (fellow Subsidiary of the Holding Company) with the Company, as April 1, 2016, the Appointed Date of Scheme.The Company acquired multi product manufacturing facility Unit 3, with a capacity of about 197 kiloliters located at Gaddapotharam Village, in Sanga Reddy District, in December, 2017.
Read More

Neuland Laboratories Ltd FAQs

Neuland Laboratories Ltd shares are currently priced at 7001.8 on NSE and 7003.15 on BSE as of 2/22/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Neuland Laboratories Ltd [NEULANDLAB] share was 344.13. The Neuland Laboratories Ltd [NEULANDLAB] share hit a 1-year low of Rs. 1561.1 and a 1-year high of Rs. 7318.3.

The market cap of Neuland Laboratories Ltd is Rs. 8983.23 Cr. as of 2/22/2024 12:00:00 AM.

The PE ratios of Neuland Laboratories Ltd is 28.39 as of 2/22/2024 12:00:00 AM.

The PB ratios of Neuland Laboratories Ltd is 7.97 as of 2/22/2024 12:00:00 AM

The Mutual Fund Shareholding was 1.83% at the end of 2/22/2024 12:00:00 AM.

You can easily buy Neuland Laboratories Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage